Solara Active Pharma Sciences LimitedQ2 FY27 Results & Financial Update
Solara Active Pharma Sciences Limited: Q2 FY27 consolidated results and company financials. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Solara Active Pharma Sciences price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Solara Active Pharma Sciences Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Solara Active Pharma Sciences reported a strong operational recovery in Q2 FY27, delivering consolidated revenue of INR 4,178 million, representing a 33% increase compared to INR 3,139 million in the corresponding period last year and a 9% growth sequentially over Q1 FY27.
Earnings before interest, tax, depreciation, and amortisation (EBITDA) more than doubled year-on-year, surging 118% to INR 769 million from INR 353 million in Q2 FY26, marking the company's highest quarterly EBITDA reported over the last five years.
The profitability turnaround was driven by consistent expansion in the Base business and substantial loss narrowing in the commodity Ibuprofen division, lifting overall EBITDA margins to 18.4% compared to 11.2% in Q2 FY26.
Profit after tax (PAT) swung back into positive territory at INR 285 million, compared to a net loss of INR 101 million in Q2 FY26 and a net profit of INR 163 million in Q1 FY27, supported by higher operating profitability and a 17% year-on-year reduction in net finance costs.
The Base business maintained strong momentum with revenue staying above INR 3,000 million for the third consecutive quarter, reaching INR 3,273 million with an EBITDA margin of 23.6%, despite continued inflationary pressures on select raw materials and solvents.
The commodity Ibuprofen business showed sequential recovery, with revenue rising 18% quarter-on-quarter to INR 905 million and EBITDA losses narrowing sharply to just INR 2 million from an INR 87 million loss in Q1 FY27, bringing the segment close to breakeven.
Balance sheet health improved significantly during the half-year, with net debt decreasing by INR 1,141 million from March 2026 levels to INR 5,000 million as of September 2026, driven by INR 1,000 million in proceeds from a rights issue and positive operating cash flows.
01 · Business model
What does Solara Active Pharma Sciences do?
Solara Active Pharma Sciences Limited operates as a specialized active pharmaceutical ingredients (API) manufacturer, focusing on complex chemistry, research-driven products, and regulated markets.
The company structures its operations into two primary streams: a higher-margin Base API business built on complex synthesis and long-term customer relationships, and a commodity Ibuprofen business serving major global brands.
Solara derives approximately 78% of its revenues from highly regulated global markets, relying on a robust product mix and established manufacturing infrastructure located across India.
The company's economic model emphasizes operational efficiency, margin expansion through complex product contributions, and systematic debt reduction to fund ongoing growth and maintenance capital expenditure.
02 · Historical context
What shaped the business before this quarter
The company previously initiated a strategic pivot to decouple from commodity exposure, directing focus toward its higher-margin Base growth API business supported by complex chemistry and lower competitive intensity.
In February 2026, the company's Board appointed strategic advisors to evaluate various restructuring and operational options specifically for the Ibuprofen business.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q2 FY27 |
|---|---|
| EBITDA | ₹76.90 Cr |
| EPS | ₹5.90 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Base business revenue grew 37% year-on-year and 6% sequentially to reach INR 3,273 million, marking the third consecutive quarter above the INR 3,000 million threshold.
Commodity Ibuprofen revenue recovered to INR 905 million, reflecting a 21% year-on-year and 18% sequential increase due to better price realisations and higher volumes.
What drove margins
Overall EBITDA margin expanded by approximately 720 basis points year-on-year to 18.4%, driven by strong Base business profitability and reduced operational losses in the Ibuprofen segment.
Base business EBITDA margin improved by approximately 440 basis points year-on-year to 23.6%, reaching INR 771 million despite persistent inflationary pressures on raw materials and solvents linked to the West Asia crisis.
Ibuprofen gross margin improved to 36.1% in Q2 FY27 from 29.0% in Q1 FY27, helping narrow the segment EBITDA loss to INR 2 million (-0.2% margin) compared to an 11.4% loss margin in Q1 FY27.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Base business recorded gross margins of INR 1,645 million (50.3% of segment revenue) and an EBITDA of INR 771 million, reinforcing its position as the primary engine for company profitability.
The Ibuprofen business is primarily focused on servicing large brands and marquee customers through established long-term strategic relationships under changing market conditions.
06 · Strategy & new businesses
How the company is trying to change its growth mix
The strategic review of the Ibuprofen business, conducted alongside the Board's advisors, has reached an advanced stage, with management expecting to provide a comprehensive update to shareholders within 12 weeks.
07 · Reported developments
What changed operationally
Q2 FY27 marked the highest quarterly EBITDA and PAT reported by the company over the last five years, reflecting robust operating performance.
Net debt reduction of INR 1,141 million during H1 FY27—comprising INR 1,000 million from rights issue proceeds and INR 141 million from operating cash flows—substantially strengthened the balance sheet.
08 · Pressure points & risks
What is not going smoothly
The company experienced ongoing inflationary pressures on select raw materials and solvents linked to ongoing geopolitical tensions in West Asia.
09 · Items worth noticing
The line items that can distort a quick read
The company reported an exceptional item of INR 45 million pertaining to losses on the sale of unusable plant and equipment at its Vizag facility during Q2 FY27.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
Consolidated net debt fell by 19% over six months to INR 5,000 million as of September 2026, down from INR 6,141 million in March 2026.
Net debt to annualized EBITDA improved significantly to approximately 1.8x as of September 2026, compared to 3.2x at the end of FY26.
Gross debt decreased by INR 944 million in H1 FY27 to INR 5,700 million, led by a INR 1,597 million reduction in working capital loans, offset by a INR 653 million increase in term loans to fund growth and maintenance capex requirements.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Vizag Facility Asset Sale
Exceptional items of INR 45 million recorded during the quarter relate to losses incurred on the sale of unusable plant and equipment at the Vizag manufacturing facility.
12 · Previous-quarter changes
What changed since the previous quarter
Consolidated revenue expanded 9% sequentially from INR 3,843 million in Q1 FY27 to INR 4,178 million in Q2 FY27, alongside a 21% increase in EBITDA.
13 · Key Q&A
The quarter, answered directly
What does Solara Active Pharma Sciences do?
Solara Active Pharma Sciences Limited operates as a specialized active pharmaceutical ingredients (API) manufacturer, focusing on complex chemistry, research-driven products, and regulated markets.
What is the clearest takeaway from Q2 FY27?
Solara Active Pharma Sciences reported a strong operational recovery in Q2 FY27, delivering consolidated revenue of INR 4,178 million, representing a 33% increase compared to INR 3,139 million in the corresponding period last year and a 9% growth sequentially over Q1 FY27.
What drove revenue or demand?
Base business revenue grew 37% year-on-year and 6% sequentially to reach INR 3,273 million, marking the third consecutive quarter above the INR 3,000 million threshold.
What mattered most for margins or profitability?
Overall EBITDA margin expanded by approximately 720 basis points year-on-year to 18.4%, driven by strong Base business profitability and reduced operational losses in the Ibuprofen segment.
What changed operationally beyond the headline numbers?
The strategic review of the Ibuprofen business, conducted alongside the Board's advisors, has reached an advanced stage, with management expecting to provide a comprehensive update to shareholders within 12 weeks.
What are the main pressure points disclosed for the quarter?
The company experienced ongoing inflationary pressures on select raw materials and solvents linked to ongoing geopolitical tensions in West Asia.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario operating profit₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Ibuprofen Strategic Review Outcome: Monitor the formal strategic update from management regarding the future business roadmap and value creation outcomes for the Ibuprofen segment within the next 12 weeks.
- 02
Leverage and Debt Trajectory: Track further movements in net debt-to-EBITDA ratios and term loan utilization as capital expenditure programs progress through subsequent quarters.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.